This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Please permit us to correct some misconceptions regarding the Physicians' Desk Reference (PDR) appearing in the article "Adverse Drug Effects, Compliance, and Initial Doses of Antihypertensive Drugs Recommended by the Joint National Committee vs the Physicians' Desk Reference," by Cohen in the March 26, 2001, issue of the ARCHIVES.¹ The PDR is designed as a communication vehicle to deliver Food and Drug Administration–approved prescribing information from pharmaceutical manufacturers to physicians and other health care professionals.

Cohen states that "information in the PDR consists mainly of the limited prerelease data that the manufacturer and the Food and Drug Administration deemed necessary for the safe and effective use of medications at the time of their approvals." That is not the case. Each year, hundreds of PDR entries are updated with substantial postmarketing information on newly noted dosing considerations, adverse drug reactions, drug interactions, precautions, and details of clinical pharmacology. Even the . . . [Full Text of this Article]

RELATED ARTICLE

Adverse Drug Effects, Compliance, and Initial Doses of Antihypertensive Drugs Recommended by the Joint National Committee vs the Physicians' Desk Reference
Jay S. Cohen
Arch Intern Med. 2001;161(6):880-885.
ABSTRACT | FULL TEXT